HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 27, Issue 1, Pages 4-18
Publisher
Springer Nature
Online
2013-06-28
DOI
10.1038/modpathol.2013.103
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2Gene Amplification in Breast Cancer
- (2012) Jane Starczynski et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Centromere 17 Copy Number Alteration: Negative Prognostic Factor in Invasive Breast Cancer?
- (2012) Stella Petroni et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections
- (2012) Hiroaki Nitta et al. Diagnostic Pathology
- ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases
- (2012) Martin C Chang et al. MODERN PATHOLOGY
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer
- (2012) Anna Żaczek et al. PATHOLOGY & ONCOLOGY RESEARCH
- Fast and Non-Toxic In Situ Hybridization without Blocking of Repetitive Sequences
- (2012) Steen H. Matthiesen et al. PLoS One
- Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations
- (2011) Kimberly H. Allison et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- HeterogeneousHER2Gene Amplification
- (2011) Alastair I. Bartlett et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Genetic heterogeneity in HER2 testing may influence therapy eligibility
- (2011) Barbara Bernasconi et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience
- (2011) L Zabaglo et al. CANCER RESEARCH
- HER2 status in breast cancer: experience of a Spanish National Reference Centre
- (2011) Marta Cuadros et al. Clinical & Translational Oncology
- Evaluation of Genetic Status of HER-2/neu and Aneusomy 17 by Fluorescence In Situ Hybridization and Comparison with Immunohistochemistry Assay from Indian Breast Cancer Patients
- (2011) Prajakta Kokate et al. Genetic Testing and Molecular Biomarkers
- Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer
- (2011) Xiaoli Zhu et al. HUMAN PATHOLOGY
- Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
- (2011) SudhaS Murthy et al. Indian Journal of Pathology and Microbiology
- Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer
- (2011) M. Elizabeth Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy
- (2011) Chun Hing Tse et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods
- (2011) J. M. S. Bartlett et al. JOURNAL OF CLINICAL PATHOLOGY
- HER2 genetic heterogeneity in breast carcinoma
- (2011) C. Ohlschlegel et al. JOURNAL OF CLINICAL PATHOLOGY
- Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
- (2011) Edith A. Perez et al. JNCI-Journal of the National Cancer Institute
- Implications of rarity of chromosome 17 polysomy in breast cancer
- (2011) Cathy B Moelans et al. LANCET ONCOLOGY
- Trastuzumab
- (2011) A. H. Boekhout et al. ONCOLOGIST
- Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer
- (2011) Kristof Egervari et al. PATHOLOGY RESEARCH AND PRACTICE
- Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options
- (2011) Rashmita Sahoo et al. Oncology Research and Treatment
- Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
- (2010) Shelly Gunn et al. BMC CANCER
- Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
- (2010) Semir Vranic et al. CANCER
- Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer
- (2010) L. Downey et al. CLINICAL CANCER RESEARCH
- How Do You Tell Whether a Breast Cancer is HER2 Positive? Ongoing Studies Keep Debate in High Gear
- (2010) C. Schmidt JNCI-Journal of the National Cancer Institute
- Management of small HER2-positive breast cancers
- (2010) Susana Banerjee et al. LANCET ONCOLOGY
- Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neuAmplification
- (2009) Matteo Brunelli et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
- (2009) Cathy B. Moelans et al. BREAST CANCER RESEARCH AND TREATMENT
- Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Be precise! The need to consider the mechanisms forCEP17copy number changes in breast cancer
- (2009) Giuseppe Viale JOURNAL OF PATHOLOGY
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis
- (2009) Caterina Marchiò et al. JOURNAL OF PATHOLOGY
- Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
- (2009) Monica M Reinholz et al. LANCET ONCOLOGY
- Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
- (2009) Uma Krishnamurti et al. MODERN PATHOLOGY
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- (2009) I-Tien Yeh et al. MODERN PATHOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Determination ofHER2Amplification by In Situ Hybridization
- (2008) John M.S. Bartlett et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
- (2008) Laura Orlando et al. BREAST
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
- (2008) Isabelle Vanden Bempt et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now